Home / Home

Gastric Cancer Research

Gastric cancer advances include HER2-directed therapy, CLDN18.2-targeting, perioperative regimens, and biomarker-informed immunotherapy.

Our Gastric Cancer Analysis

  • August 20, 2026JAMA Oncology

    Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

    A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

Related topics: Fixed-Duration and De-escalated Therapy